Authorized purpose: Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Clinical role
Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Images and patients
CT/CTA · Spine
Key limitation
Keep in mind: The FDA material states that the software does not diagnose, recommend treatment, or select implants; use is limited to the labeled adult spine-surgery workflow.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Spine Input: The exact submission's labeled medical-image, measurement, or clinical-workflow inputs.
Who uses it?Intended users: Spine surgeons and the relevant surgical team.
What does the software produce?Output: Visualizations, segmentations, measurements, reconstructions, planning information, or other software outputs described in the exact FDA labeling.
What is its most important limitation?Key limitation: The FDA material states that the software does not diagnose, recommend treatment, or select implants; use is limited to the labeled adult spine-surgery workflow.
Clinical takeaway. Clinical role: Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a standalone performance assessment on 181 subjects, with ground truth segmentation available with the dataset; the 95% LCI of mean DICE coefficient for all spine objects in aggregate was 0.96025. A confirmatory non-inferiority performance validation study using 54 subjects from four additional clinical sites showed non-inferior results for all aggregate and individual object performance. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
The FDA material states that the software does not diagnose, recommend treatment, or select implants; use is limited to the labeled adult spine-surgery workflow.
The exact FDA document reports a standalone performance assessment on 181 subjects, with ground truth segmentation available with the dataset; the 95% LCI of mean DICE coefficient for all spine objects in aggregate was 0.96025. A confirmatory non-inferiority performance validation study using 54 subjects from four additional clinical sites showed non-inferior results for all aggregate and individual object performance. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "a Standalone Performance Assessment (SAPA) was developed in accordance with Performance Validation requirements" … "Ground truth segmentation per an established, acceptable method was available with the dataset". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports a standalone performance assessment on 181 subjects, with ground truth segmentation available with the dataset; the 95% LCI of mean DICE coefficient for all spine objects in aggregate was 0.96025. A confirmatory non-inferiority performance validation study using 54 subjects from four additional clinical sites showed non-inferior results for all aggregate and individual object performance. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "a Standalone Performance Assessment (SAPA) was developed in accordance with Performance Validation requirements" … "Ground truth segmentation per an established, acceptable method was available with the dataset". Read from the exact FDA decision document on 2026-11-14.
No exact-product, version-specific sensitivity endpoint was established for this submission in the evidence set.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact-product, version-specific specificity endpoint was established for this submission in the evidence set.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K253628 FDA evidence package for Auto-Seg (SO-0012), Spine Auto-Seg (SO-0012)
DesignFDA submission-level decision material with device, software, performance, safety, and/or usability verification as applicable; not independent clinical validation.
PopulationPopulation and workflow are limited to the exact FDA labeling summarized for this submission.
Scopeexact submission
Tested versionExact FDA submission release; version not separately stated in the public decision material
IndependenceSponsor or vendor study
K253628
Evidence submitted for the exact FDA decision is not independent clinical validation. Local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K253628 by native exact submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, dental, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: The exact submission's labeled medical-image, measurement, or clinical-workflow inputs.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Imports spine and pelvis CT studies as DICOM from an encrypted USB workflow and exports results to encrypted USB; local round-trip acceptance remains necessary.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: A standard PC with GPU in an office environment is described; hosting, availability, and service terms are not established.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Visualizations, segmentations, measurements, reconstructions, planning information, or other software outputs described in the exact FDA labeling.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Visualizations, segmentations, measurements, reconstructions, planning information, or other software outputs described in the exact FDA labeling.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Imports spine and pelvis CT studies as DICOM from an encrypted USB workflow and exports results to encrypted USB; local round-trip acceptance remains necessary.
Use by the qualified healthcare professionals identified for the exact labeled workflow; site-specific competency and training requirements remain to be established locally.
Imports spine and pelvis CT studies as DICOM from an encrypted USB workflow and exports results to encrypted USB; local round-trip acceptance remains necessary.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The FDA material states that the software does not diagnose, recommend treatment, or select implants; use is limited to the labeled adult spine-surgery workflow.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the evidence set; productivity or value claims require local evidence.
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes; exact monitoring thresholds and vendor commitments are unknown.
exact submission · checked 2026-09-04
Establish ownership for data quality, overrides, drift, incidents, recalls, and change control.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-19Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, fda decision summary, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found in the evidence set. Obtain a written quote covering license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, downtime, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Security controls, hosting boundaries, audit behavior, identity management, and incident commitments for the exact configuration are not established in the public FDA decision material.
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-04 - Exact FDA submission
Post-deployment monitoring, drift thresholds, alerting, and revalidation commitments for the exact configuration require vendor and site confirmation.
AI-Rad Companion (Musculoskeletal) is an image processing software that provides quantitative and qualitative analysis from previously acquired Computed Tomography DICOM images to support radiologists and physicians from emergency medicine, specialty care, urgent care, and general practice in the evaluation and assessment of musculoskeletal disease. It provides the following functionality: • Segmentation of vertebras • Labelling of vertebras • Measurements of heights in each vertebra and indication if they are critically different • Measurement of mean Hounsfield value in volume of interest within vertebra. Only DICOM images of adult patients are considered to be valid input.
Authorized purpose: Provides quantitative and qualitative analysis of previously acquired CT DICOM images to support radiologists and physicians in musculoskeletal-disease assessment.
Authorized purpose: Analyzes existing CT images in DICOM format from adults aged 30 years and older to estimate average areal BMD of spinal bones and flag low bone density below a preset threshold, including opportunistic scans without a phantom; it does not replace DXA or other dedicated BMD testing.
Authorized purpose: Use with CT images to automatically generate anatomically focused multi-planar spine reformats, apply vertebral-body and intervertebral-disc labels, and export the results to predetermined DICOM destinations for review.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.